JP2010511727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511727A5 JP2010511727A5 JP2009540422A JP2009540422A JP2010511727A5 JP 2010511727 A5 JP2010511727 A5 JP 2010511727A5 JP 2009540422 A JP2009540422 A JP 2009540422A JP 2009540422 A JP2009540422 A JP 2009540422A JP 2010511727 A5 JP2010511727 A5 JP 2010511727A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- optionally substituted
- lower alkyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86851706P | 2006-12-04 | 2006-12-04 | |
| PCT/US2007/086380 WO2008070661A1 (en) | 2006-12-04 | 2007-12-04 | Substituted pyrimidines as adenosine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511727A JP2010511727A (ja) | 2010-04-15 |
| JP2010511727A5 true JP2010511727A5 (enExample) | 2012-02-02 |
Family
ID=39272263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540422A Withdrawn JP2010511727A (ja) | 2006-12-04 | 2007-12-04 | アデノシン受容体アンタゴニストとしての置換ピリミジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100234341A1 (enExample) |
| EP (1) | EP2121662A1 (enExample) |
| JP (1) | JP2010511727A (enExample) |
| CN (1) | CN101679371A (enExample) |
| WO (1) | WO2008070661A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| CA2944788C (en) | 2009-06-29 | 2023-08-22 | Agios Pharmaceuticals, Inc. | Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same |
| CA2793835C (en) | 2009-10-21 | 2021-07-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| KR101873543B1 (ko) | 2011-05-03 | 2018-07-02 | 아지오스 파마슈티컬스 아이엔씨. | 치료에 사용하기 위한 피루베이트 키나아제 활성제 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2763533B1 (en) * | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
| CN102772800A (zh) * | 2011-12-20 | 2012-11-14 | 同济大学 | 靶向腺苷受体a2bar的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| SG11201403878QA (en) | 2012-01-06 | 2014-08-28 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| HK1213798A1 (zh) | 2012-10-15 | 2016-07-15 | 安吉奥斯医药品有限公司 | 治療性化合物和組合物 |
| US9073875B2 (en) | 2012-11-20 | 2015-07-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| WO2014159690A1 (en) | 2013-03-12 | 2014-10-02 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| EP2991977B1 (en) * | 2013-05-01 | 2020-07-22 | F.Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| CA2917671A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| NZ715738A (en) | 2013-07-11 | 2021-06-25 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| CN103626741A (zh) * | 2013-11-26 | 2014-03-12 | 苏州大学 | 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物 |
| CN103664908A (zh) * | 2013-12-10 | 2014-03-26 | 苏州大学 | 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物 |
| CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| KR20170055531A (ko) * | 2014-09-17 | 2017-05-19 | 아이언우드 파마슈티컬스, 인코포레이티드 | 에스지씨 자극제 |
| DK3307271T3 (da) | 2015-06-11 | 2023-10-09 | Agios Pharmaceuticals Inc | Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer |
| DK3362066T3 (da) | 2015-10-15 | 2021-11-22 | Les Laboratoires Servier Sas | Kombinationsterapi til behandling af maligniteter |
| MA71411A (fr) | 2015-10-15 | 2025-04-30 | Les Laboratoires Servier | Polythérapie pour le traitement de tumeurs malignes |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| WO2018064092A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
| JP6997197B2 (ja) | 2017-01-23 | 2022-01-17 | カデント セラピューティクス，インコーポレーテッド | カリウムチャネルモジュレーター |
| CN107286146B (zh) * | 2017-07-05 | 2020-07-31 | 上海肇钰医药科技有限公司 | 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途 |
| WO2019119206A1 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
| CN115151534B (zh) * | 2020-02-14 | 2024-02-06 | 南京药石科技股份有限公司 | 白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| DE3905364A1 (de) * | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
| DE3922735A1 (de) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
| DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| WO2000027824A1 (en) * | 1998-11-12 | 2000-05-18 | Elan Pharmaceuticals | Substituted pyrimidine compositions and methods of use |
| CN1438890A (zh) * | 2000-02-25 | 2003-08-27 | 弗·哈夫曼-拉罗切有限公司 | 腺苷受体调制剂 |
| JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| WO2002060392A2 (en) * | 2001-01-31 | 2002-08-08 | Synaptic Pharmaceutical Corporation | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| SMAP200600024A (it) * | 2003-12-15 | 2006-07-19 | Almirall Prodesfarma Ag | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia |
| US20080275064A1 (en) * | 2005-04-11 | 2008-11-06 | Deborah Slee | Substituted Pyrimidines as Adenosine Receptor Antagonists |
-
2007
- 2007-12-04 JP JP2009540422A patent/JP2010511727A/ja not_active Withdrawn
- 2007-12-04 WO PCT/US2007/086380 patent/WO2008070661A1/en not_active Ceased
- 2007-12-04 US US12/517,546 patent/US20100234341A1/en not_active Abandoned
- 2007-12-04 EP EP07865169A patent/EP2121662A1/en not_active Withdrawn
- 2007-12-04 CN CN200780050872A patent/CN101679371A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511727A5 (enExample) | ||
| JP2010511727A (ja) | アデノシン受容体アンタゴニストとしての置換ピリミジン | |
| US8796284B2 (en) | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | |
| US10717711B2 (en) | Amino quinazolines as kinase inhibitors | |
| JP7105781B2 (ja) | ベンズイミダゾール誘導体、調製方法およびそれらの使用 | |
| AU2019283921A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| JP2007514003A6 (ja) | アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン | |
| JP2007514003A (ja) | アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン | |
| SK14282002A3 (sk) | Deriváty 8-chinolínxantínu a 8-izochinolínxantínu, farmaceutická kompozícia, ktorá ich obsahuje, ich použitie a spôsob ich prípravy | |
| WO2015069310A1 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses | |
| JPWO2009099163A1 (ja) | Ｐｉ３ｋ阻害剤としてのピロロピリミジン誘導体及びその用途 | |
| US20100249084A1 (en) | Substituted pyrimidines as adenosine receptor antagonists | |
| CN112313207A (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
| CN109810098B (zh) | 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂 | |
| EP1888565B1 (en) | 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists | |
| AU2016341259A1 (en) | Pyridone derivatives and their use as kinase inhibitors | |
| US20210300922A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| ZA200604823B (en) | 2,6 Bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists | |
| WO2025236004A1 (en) | Stat6 inhibitors and uses thereof | |
| Alhousami et al. | Synthesis Characterization and Antibacterial Activities of Some New pyridazines and Thieno [2, 3-c] pyridazines. | |
| HUP0302440A2 (hu) | Amino-kinolin származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények | |
| HUP0401467A2 (en) | Aminoquinoline derivatives, process for producing them and their use as adenosine a3 ligands |